Scarica l'app Stockscreener
3.2305
1.56%
-0.0495
Precedente Chiudi:
$3.28
Aprire:
$3.25
Volume 24 ore:
300.45K
Relative Volume:
0.47
Capitalizzazione di mercato:
$201.50M
Reddito:
$56.91M
Utile/perdita netta:
$-9.06M
Rapporto P/E:
26.92
EPS:
0.12
Flusso di cassa netto:
$-79.97M
1 W Prestazione:
-15.26%
1M Prestazione:
-16.35%
6M Prestazione:
-24.21%
1 anno Prestazione:
-56.43%
Intervallo 1D:
$3.16
$3.328
Intervallo di 1 settimana:
$3.16
$3.84
Portata 52W:
$2.9511
$21.88
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| MGNX | 3.23 | 201.50M | 56.91M | -9.06M | -79.97M | 0.12 |
| VRTX | 450.27 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.61 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts - MarketBeat
MacroGenics' SWOT analysis: biotech stock faces pipeline hurdles amid cash strength - Investing.com India
MacroGenics downgraded to market perform by JMP, price target removed - MSN
FY2024 Earnings Estimate for MacroGenics Issued By B. Riley - MarketBeat
StockNews.com Upgrades MacroGenics (NASDAQ:MGNX) to Buy - MarketBeat
MacroGenics FY2024 EPS Estimate Increased by HC Wainwright - MarketBeat
Leerink Partnrs Increases Earnings Estimates for MacroGenics - MarketBeat
MacroGenics puts the brakes on vobra duo development - The Pharma Letter
MacroGenics downgraded to Market Perform from Outperform at JMP Securities - TipRanks
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights - Benzinga
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript - Insider Monkey
MacroGenics (NASDAQ:MGNX) Rating Lowered to "Market Perform" at JMP Securities - MarketBeat
MacroGenics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire
MacroGenics (MGNX) to Present at Guggenheim and Stifel Healthcare Conferences | MGNX Stock News - StockTitan
Earnings call: MacroGenics reports a revenue jump to $110.7 million By Investing.com - Investing.com South Africa
Earnings call: MacroGenics reports a revenue jump to $110.7 million - Investing.com India
MacroGenics Margenza rights sale a positive, says Leerink - TipRanks
MacroGenics (NASDAQ:MGNX) Receives Neutral Rating from HC Wainwright - MarketBeat
MacroGenics Inc earnings beat by $0.69, revenue topped estimates - Investing.com Australia
Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments - GuruFocus.com
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - GlobeNewswire
MacroGenics Inc. Reports Strong Revenue Growth - TipRanks
MacroGenics: Q3 Earnings Snapshot - Barchart
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript - Nasdaq
Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings - Yahoo Finance
MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
MacroGenics Q3 2024 Earnings Preview - MSN
Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Effective February 28, 2025 - Marketscreener.com
Q3 2024 MacroGenics Inc Earnings Call Transcript - GuruFocus.com
Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments By GuruFocus - Investing.com Canada
Macrogenics Earnings Preview - Benzinga
Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result - GuruFocus.com
MacroGenics (NASDAQ:MGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
Masashi Miyamoto to become chairman and CEO of Kyowa Kirin - BioCentury
MacroGenics CEO Scott Koenig to resign early next year - Investing.com India
MacroGenics Announces Leadership Transition - GlobeNewswire
MacroGenics (MGNX) Scheduled to Post Earnings on Tuesday - MarketBeat
MacroGenics Co-Founder Koenig Stepping Down as President, CEO - MarketWatch
MacroGenics CEO Scott Koenig to resign early next year By Investing.com - Investing.com UK
Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year - Marketscreener.com
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - GlobeNewswire
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):